Cite
MLA Citation
R Garcia-Sanz et al.. “Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).” Annals of oncology, vol. 30, 2019, pp. 612–620. http://access.bl.uk/ark:/81055/vdc_100094045739.0x000040